AIS's Health Business Daily is a daily email newsletter with strategic business stories written by experienced AIS Health reporters, as well as other information of interest to health care business leaders — including news from the nation’s leading health insurers, developments from the federal and state governments that impact the health care industry, and exclusive datapoints from Subscribe now to get an issue delivered to your inbox every morning!
December 18, 2017
Today's Featured Story
MedPAC Recommends Part D Changes to Boost Biosimilar Use
Attendees of a recent Medicare Payment Advisory Commission (MedPAC) meeting discussed biosimilars within Medicare Part D, and presenters offered recommendations that could boost their uptake by plan sponsors....  Read Full Story
Subscribe to AIS Health's Specialty Pharmacy News

Today's AIS Health Datapoint
71% ... of covered lives in the United States have access to Advair Diskus, an Asthma/COPD inhalant, on the preferred tier. Advair is one of the most commonly prescribed asthma drugs on the market, but is costly, with the price of a dose ranging between $290 and $475. Several pharmaceutical manufacturers are in the process of developing generic alternatives to Advair.

People on the Move

The Featured Story of the day may be accessed on the day it is transmitted without logging in to Thereafter, you may need to log in to access the Featured Story. If you haven’t yet registered on, please take a minute to create a free account now and get free access to thousands of articles, blogs and much more.

Questions or suggestions about the content in AIS's HEALTH BUSINESS DAILY should be directed to Executive Editor Jill Brown at

AIS's HEALTH BUSINESS DAILY is copyrighted and protected by federal law. The re-use of its content is restricted (see below). However, you are permitted to forward this email to as many of your friends and colleagues as you wish, or better yet have them sign up for their own copy at atlantic_subscription.cfm

Copyright © 2017 Managed Markets Insight & Technology, LLC. All rights reserved. It is not permissible to include all or any portion of this content on any Web site, intranet or electronic network or in any print publication, without AIS's written permission in advance. Contact for more information.